Access cutting-edge transthyretin amyloidosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access transthyretin amyloidosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related transthyretin amyloidosis treatment provided free
Transthyretin cardiac amyloidosis (ATTR-CA) is a relentlessly progressive disease that can progress to end stage heart failure, at which point recently approved transthyretin production silencing or structure stabilizing therapies provide no clinical benefit. For well-selected individuals, heart transplantation is an excellent therapeutic option to improve survival. Historically, concomitant liver transplantation has been used to halt the progression of non-cardiac transthyretin amyloidosis (ATT
Sponsor: University of Texas Southwestern Medical Center
Check if you qualify for this transthyretin amyloidosis clinical trial in New York, NY
If you're searching for transthyretin amyloidosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced transthyretin amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.